Form 4: UroGen Pharma Director Fred E. Cohen Acquires 10,000 Stock Options

Director Fred E. Cohen acquired 10,000 stock options in UroGen Pharma Ltd. on August 6, 2024.

Summary

• Fred E. Cohen, a director of UroGen Pharma Ltd., acquired 10,000 stock options on August 6, 2024.
• The exercise price of the stock options is $15.16.
• The options vest in equal quarterly installments over one year, contingent upon continuous service.
• The expiration date for the options is August 6, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is part of a compensation package.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance, but the vesting schedule of the options is contingent on continuous service.

Industry Context

This is a standard disclosure of insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates